The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction

Urology

Volumn 83, Issue 2, 2014, Pages 508.e7-508.e12

  Yilmaz, Didem ^a   Bayatli, Nur ^a   Un, Ozge ^a   Kadowitz, Philip J ^b   Sikka, Suresh C ^c   Gur, Serap ^a,c  

^a ANKARA UNIVERSITY   (Turkey)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AVANAFIL; GLUCOSE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOSE RESPONSE; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; MUSCLE RELAXATION; NEWBORN; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS;

ANIMALS; ANIMALS, NEWBORN; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; INJECTIONS; MALE; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84895069020     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.10.021     Document Type: Article

References (30)

1. S.K. Jain L-cysteine supplementation as an adjuvant therapy for type-2 diabetes Can J Physiol Pharmacol 90 2012 1061 1064
2. L.S. Malavige, and J.C. Levy Erectile dysfunction in diabetes mellitus J Sex Med 6 2009 1232 1247
3. H.A. Feldman, I. Goldstein, and D.G. Hatzichristou et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study J Urol 151 1994 54 61
4. L. Deyoung, E. Chung, and J.R. Kovac et al. Daily use of sildenafil improves endothelial function in men with type 2 diabetes J Androl 33 2012 176 180
5. I. Saenz de Tejada, I. Goldstein, and K. Azadzoi et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence N Engl J Med 320 1989 1025 1030
6. I.P. Luttrell, M. Swee, and B. Starcher et al. Erectile dysfunction in the type II diabetic db/db mouse: impaired venoocclusion with altered cavernosal vasoreactivity and matrix Am J Physiol Heart Circ Physiol 294 2008 H2204 H2211
7. R.T. Ellati, A.O. Dokun, and P.K. Kavoussi et al. Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus J Sex Med 10 2013 362 369
8. X. Zhang, N.D. Kanika, and A. Melman et al. Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes Am J Physiol Endocrinol Metab 302 2012 E32 E42
9. A.S. Akarte, B.P. Srinivasan, and S. Gandhi A novel long acting DPP-IV inhibitor PKF-275-055 stimulates beta-cell proliferation resulting in improved glucose homeostasis in diabetic rats Biochem Pharmacol 83 2012 241 252
10. M.M. Garcia, T.M. Fandel, and G. Lin et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells J Sex Med 7 2010 89 98
11. S. Jesmin, I. Sakuma, and A. Salah-Eldin et al. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes J Mol Endocrinol 31 2003 401 418
12. F.S. Carneiro, F.R. Giachini, and Z.N. Carneiro et al. Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177 J Sex Med 7 2010 3620 3634
13. T.J. Bivalacqua, M.F. Usta, and H.C. Champion et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats Int J Impot Res 16 2004 21 29
14. Y. Chen, X.X. Li, and H.C. Lin et al. The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism Asian J Androl 14 2012 616 620
15. S. Fukuhara, A. Tsujimura, and H. Okuda et al. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings J Sex Med 8 2011 1061 1071
16. J. Kotera, H. Mochida, and H. Inoue et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction J Urol 188 2012 668 674
17. C. Zhao, S.W. Kim, and D.Y. Yang et al. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial BJU Int 110 2012 1801 1806
18. R. Wang, A.L. Burnett, and W.H. Heller et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability J Sex Med 9 2012 2122 2129
19. S. Gur, P.J. Kadowitz, and A. Gokce et al. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension Curr Drug Metab 14 2013 265 269
20. W.J. Hellstrom, M.T. Freier, and E.C. Serefoglu et al. A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction BJU Int 111 2013 137 147
21. J.P. Mulhall, A.L. Burnett, and R. Wang et al. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy J Urol 189 2013 2229 2236
22. B.R. Goyal, K. Parmar, and R.K. Goyal et al. Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats Pharmacol Rep 63 2011 956 966
23. M. Albersen, G. Lin, and T.M. Fandel et al. Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction Urology 78 2011 476.e1 476.e8
24. X.H. Zhang, S. Filippi, and A. Morelli et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes J Sex Med 3 2006 253 264 discussion 264-255, author reply 265-256
25. L.X. De Young, T. Domes, and K. Lim et al. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats Eur Urol 54 2008 213 220
26. F.S. Lizarte, M. Morgueti, and C.R. Tirapelli et al. Chronic alcoholism associated with diabetes impairs erectile function in rats BJU Int 105 2010 1592 1597
27. N. Villalba, P. Martinez, and A.M. Briones et al. Differential structural and functional changes in penile and coronary arteries from obese Zucker rats Am J Physiol Heart Circ Physiol 297 2009 H696 H707
28. K.H. Elcioglu, L. Kabasakal, and S. Cetinel et al. Changes in caveolin-1 expression and vasoreactivity in the aorta and corpus cavernosum of fructose and streptozotocin-induced diabetic rats Eur J Pharmacol 642 2010 113 120
29. J.S. Kalsi, D.J. Ralph, and D.J. Madge et al. A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats Int J Impot Res 16 2004 479 485
30. S. Gur, P.J. Kadowitz, and W.J. Hellstrom A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats J Sex Med 7 2010 3341 3350